IOVA - IOVANCE BIOTHERAPEUTICS, INC.
IEX Last Trade
7.5
-2.660 -35.467%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$10.16
-2.66
-26.18%
Fundamental analysis
22%
Profitability
25%
Dept financing
2%
Liquidity
49%
Performance
17%
Performance
5 Days
1.49%
1 Month
-19.20%
3 Months
-18.76%
6 Months
-11.36%
1 Year
-10.19%
2 Year
22.39%
Key data
Stock price
$7.50
DAY RANGE
$7.44 - $10.16
52 WEEK RANGE
$7.44 - $18.33
52 WEEK CHANGE
$3.60
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Frederick G. Vogt
Region: US
Website: iovance.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: iovance.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Iovance Biotherapeutics, Inc. focuses on developing and commercializing cancer immunotherapy products. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma. The company was incorporated in 2007 and is headquartered in San Carlos, California.
Recent news